AlzeCure Pharma AB (AC6) AI Stock Analysis

3 Followers

AlzeCure Pharma AB

(Frankfurt:AC6)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverageThe company has comparatively low financial leverage, which limits interest and refinancing pressure relative to its equity base. This provides more balance-sheet flexibility than a highly indebted biotech and can help preserve strategic options while pipeline programs progress.

Negative Factors

No commercial revenueZero reported revenue means the company has not yet established a commercial income stream to offset research and development spending. Until a candidate is partnered successfully or reaches approval, financial performance remains dependent on funding rather than recurring product sales.

AlzeCure Pharma AB (AC6) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 79.46M
Dividend Yield: ―
Average Volume (3M): 1,354
Price to Earnings (P/E): 10.7
Beta (1Y): -0.37
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 10
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

AlzeCure Pharma AB Business Overview & Revenue Model

Company Description

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates base...

AlzeCure Pharma AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:AC6 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CAMX	78Outperform	SEK 45.12B	58.66	16.50%	―	2.96%	-4.07%
SE:SANION	77Outperform	SEK 1.64B	8.89	29.71%	―	24.98%	-31.44%
SE:BIOA.B	65Neutral	SEK 27.51B	260.50	5.18%	0.69%	-46.09%	-90.13%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ALZ	44Neutral	SEK 100.82M	-1.88	-15.44%	―	-100.00%	40.79%
SE:IRLAB.A	38Underperform	SEK 126.11M	-1.30	-97.06%	―	-21.20%	68.24%

* Healthcare Sector Average

Performance Comparison

DE:AC6 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:AC6	AlzeCure Pharma AB	0.54	0.34	170.71%
SE:CAMX	Camurus AB	745.00	123.00	19.77%
SE:ALZ	Alzinova AB	0.32	-1.23	-79.42%
SE:BIOA.B	BioArctic AB Class B	310.00	25.49	8.96%
SE:SANION	Saniona AB	11.91	-4.31	-26.57%
SE:IRLAB.A	IRLAB Therapeutics AB Class A	0.85	-1.37	-61.82%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

AlzeCure Pharma AB AI Stock Analysis